Accelerated vs. Standard Continuous Renal Replacement Therapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 408 participants.
Also called NCT06696235
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 408 participants
- Sponsor
- Registry
-
NCT06696235
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06696235. Randomized; no masking; primary purpose treatment. Start 2024-12-31 (actual); primary completion 2028-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Accelerated vs. Standard Continuous Renal Replacement Therapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator
- Acronym
- REDUCE-ECMO
- Condition
- Cardiogenic Shock
- Condition
- Acute Kidney Injury
- Intervention (Device)
- Early initiation of continuous renal replacement therapy
- Intervention (Device)
- Standard initiation of continuous renal replacement therapy
- Lead sponsor
- Samsung Medical Center
Record details
- Record id
cardio:ct-nct06696235- Content hash
5d4cec9f52bf62eafc5027aa100ee491f4a0bc4f57f8e6f66d9652527cad1214